Instil Bio(US:TIL)2026-03-27 11:00Financial Position - As of December 31, 2025, Instil Bio had a total cash position of $76.3 million, down from $115.1 million as of December 31, 2024[4]. - Instil Bio's total assets decreased to $203.5 million as of December 31, 2025, from $263.6 million in 2024, a decline of 23%[17]. - Instil Bio's total stockholders' equity decreased to $113.9 million as of December 31, 2025, down from $169.4 million in 2024, a decrease of 33%[17]. - The company expects its cash position to fund its current operating plan beyond 2027[6]. Expenses - Research and development expenses for the fourth quarter of 2025 were $3.5 million, compared to $1.1 million in the same quarter of 2024, representing a 218% increase[7]. - General and administrative expenses decreased to $6.1 million in Q4 2025 from $10.4 million in Q4 2024, a reduction of 41%[8]. - The company reported restructuring and impairment charges of $16.6 million for the full year 2025, compared to $7.5 million in 2024, marking a 121% increase[9]. Net Loss - The net loss for the fourth quarter of 2025 was $8.2 million, an improvement from a net loss of $11.9 million in Q4 2024, reflecting a 31% reduction[10]. - Non-GAAP net loss per share for the full year 2025 was $6.91, compared to $7.59 for the full year 2024, indicating a 9% improvement[10]. Strategic Development - Instil Bio plans to pursue potential acquisitions and in-licensing opportunities to enhance its strategic development and pipeline[3].